Myeloproliferative Neoplasms
Texas MPN Workshop 2021: updates on interferons for MPNs
Many clinical trials are currently investigating the potential benefits of interferons in the treatment of myeloproliferative neoplasms (MPNs), in particular…
Date: 27th August 2021
EHA 2021: key trial updates in myelofibrosis
The breakthrough discovery of upregulation of the JAK-STAT signaling pathway as the driving force behind myeloproliferative neoplasms (MPNs) has led…
Date: 20th July 2021
The MPN Sessions: highlights from EHA and ASCO 2021
Over the past decade there has been a vast increase in the number of clinical trials taking place in the…
Date: 16th July 2021
The Post-EBMT VJSessions from VJHemOnc
The 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) was held virtually this year and…
Date: 7th April 2021
The MPN Sessions: Rapidly advancing genomic discoveries and treatment strategies in MPNs
Mechanistically, myeloproliferative neoplasms (MPNs), comprising primary myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), were a mystery for many…
Date: 19th February 2021
Moving forward in MPN: timing driver mutations and novel therapies from ASH 2020
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of rare myeloid neoplasms characterized by the abnormal proliferation of hematopoietic stem cells…
Date: 11th January 2021
SOHO 2020: Next questions in hematological malignancies
The Society of Hematologic Oncology (SOHO) 2020 Virtual Annual Meeting brought together global leading experts in hematological oncology who updated…
Date: 25th September 2020
The MPN Sessions: pathobiology, therapeutic strategies & clinical trials
Myeloproliferative neoplasms (MPNs) are a group of hematopoietic stem cell diseases characterized by the excessive production of one or more…
Date: 15th September 2020
MPNs highlights at EHA 2020: clinical trials, novel therapies & pitfalls
It is an exciting time in terms of therapeutic progress for myeloproliferative neoplasms (MPN). In recent years, there have been…
Date: 6th August 2020
The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resource allocation
The ongoing COVID-19 pandemic caused by SARS-CoV-2 is an international public health issue and patients with cancer consistently demonstrate poorer…
Date: 28th July 2020
Systemic mastocytosis: current landscape, novel agents and COVID-19
Systemic mastocytosis (SM) is a rare hematological neoplasm. Advanced systemic mastocytosis can be sub-classified into either aggressive SM, SM with…
Date: 2nd June 2020